Racura Oncology Ltd (ASX: RAC)
Health Care · Biotechnology · AU
AU$1.82
-5.47% today · -60.2% 1Y
Racura Oncology Ltd (ASX: RAC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $248.34M and employs 5 people.
Over the last twelve months the share price has lost 60.2%, trading between 1.77 and 4.90.
Tweenvest scores Racura Oncology Ltd across four factors: quality 40/100, value 57/100. Its strongest factor is value.
RAC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $248.34M
- Revenue (TTM)
- $1.94M
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 0.91
- 52-week high
- AU$4.90
- 52-week low
- AU$1.77
- Avg volume (3M)
- —
- Shares outstanding
- 196.07M
- Employees
- 5
- Next earnings
- —
About Racura Oncology Ltd
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.
- ISIN
- AU000000RAC3
- Founded
- 2011
- Listed since
- Jul 13, 2016
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| TriSalus Life Sciences, Inc.NasdaqGM: TLSI | $249.99M | $4.06 | -6.02% |
| Zentalis Pharmaceuticals, Inc.NasdaqGM: ZNTL | $249.93M | $2.64 | +4.76% |
| HighTide Therapeutics, Inc.SEHK: 2511 | $249.35M | HK$3.43 | -2.14% |
| AC Immune SANasdaqGM: ACIU | $248.57M | $2.50 | -8.26% |
| Q32 Bio Inc.NasdaqCM: QTTB | $248.28M | $8.34 | +1.34% |
| Shandong Boan Biotechnology Co., Ltd.SEHK: 6955 | $245.84M | HK$3.10 | +2.31% |
| Acepodia, Inc.TPEX: 6976 | $244.38M | NT$13.40 | +4.69% |
| Oryzon Genomics S.A.BME: ORY | $243.20M | €2.65 | +0.76% |
Figures last refreshed Oct 11, 2026.